Mats Enlund: Exploring the Role of Anesthetics in Cancer Treatment

Mats Enlund is a researcher whose work has the potential to change the way we approach cancer treatment. With a background in anesthesiology and intensive care, he has become a key figure in investigating how different anesthetics may impact the long-term survival of cancer patients. In a field where every percentage point in survival matters, Enlund and his research team are focusing on an aspect of cancer surgery that has received little attention: the choice of anesthetic.

A pivotal moment in Enlund's career came when he discovered, through a retrospective study, a possible link between the choice of anesthetic and the survival rates of cancer patients. The study, published in 2014, indicated that patients who received the intravenous anesthetic propofol during their surgeries had better survival outcomes compared to those who received the inhaled anesthetic sevoflurane. This observation sparked a comprehensive research project with the potential to revolutionize cancer care.

However, retrospective studies are rarely conclusive, meaning that these initial findings cannot be taken at face value without further investigation. For Enlund and his team, it became a priority to either confirm or refute these results through more rigorous research methods, particularly randomized controlled trials (RCTs). Currently, there are only two ongoing RCTs in this area, and neither includes ovarian cancer, one of the deadliest forms of gynecological cancer.

The hypothesis driving Enlund's largest ongoing study is simple yet potentially groundbreaking: If propofol can improve the 5-year survival rate of cancer patients by at least 5 percentage points compared to sevoflurane, this would result in an annual survival gain of nearly 10,000 lives worldwide for ovarian cancer alone. A difference of this magnitude is comparable to the effects of adjunct therapies such as chemotherapy.

To investigate this hypothesis, Enlund and his team have begun utilizing Swedish quality registries. By combining data on cancer patients' survival with information on which anesthetics were used during their surgeries, they hope to determine whether the choice of anesthetic plays a crucial role in long-term survival. This methodology allows the researchers to complement ongoing RCTs and extend the investigation to other types of cancer, including those that are rarely studied due to their relatively low incidence but high mortality.

The significance of the research findings

Regardless of whether the research results reveal a significant difference, Enlund's work will have far-reaching implications for how we approach cancer treatments. If propofol proves to be the superior choice, it could lead to widespread changes in how cancer surgeries are conducted globally. Conversely, if the hypothesis is disproven, it will also be valuable, as

hospitals can continue using sevoflurane without the need for costly changes in equipment and staff training.

Mats Enlund's research highlights an important yet often overlooked aspect of cancer surgery. By challenging established practices and exploring new possibilities, he is pushing the boundaries of science toward a future where every decision in the treatment process can be critical to a patient's survival. His work serves as an inspiring example of how a researcher, driven by curiosity and deep commitment to patients, can make a real difference in people's lives.

Interview conducted and text written by Matilda Norlen & Louise Österberg